Quick View
| Metric | Current Period | Same Period Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥663.33B | ¥578.46B | +14.7% |
| Operating Income | ¥319.62B | ¥273.34B | +16.9% |
| Profit Before Tax | ¥329.22B | ¥271.83B | +21.1% |
| Net Income | ¥231.75B | ¥194.39B | +19.2% |
| ROE | 11.4% | 9.6% | - |
Executive Summary
Both revenue and earnings achieved double-digit growth, resulting in higher revenue and profit with profitability improving further from the previous year. Revenue was ¥663.33B (+14.7% YoY), operating income was ¥319.62B (+16.9%), profit before tax was ¥329.22B (+21.1%), and net income attributable to owners of the parent was ¥231.75B (+19.2%). Operating income and net income grew at a faster pace than revenue, confirming an expansion in profitability through improvements in gross margin and the SG&A ratio. Regarding dividends, the interim dividend decreased from ¥125 in the same period of the previous year to ¥66 due to the absence of the 100th anniversary commemorative dividend paid in the same period of the previous year.
Factors Affecting Performance
【Revenue】Revenue increased 14.7% YoY to ¥663.33B. Cost of sales was ¥197.01B (+12.0%), below the growth rate of revenue, and the gross margin improved by +0.7pt to 70.3% from 69.6% in the previous year. Revenue growth exceeded the increase in costs, suggesting that improvements in pricing and product mix contributed to the revenue increase.
【Profit and Loss】Operating income increased 16.9% YoY to ¥319.62B, and the operating margin improved by +0.9pt to 48.2% from 47.3% in the previous year. The SG&A ratio declined slightly to 8.7% from 8.9% in the previous year. Although R&D expenses increased to ¥89.64B (+3.5%), R&D expenses as a percentage of revenue declined to 13.5% from 15.0%, indicating that R&D expense growth was moderate relative to revenue growth and contributed to the improvement in profit margins. Profit before tax was ¥329.22B (+21.1%), while net income after deducting income taxes and other taxes of ¥97.47B (effective tax rate: 29.6%; previous year: 28.5%) was ¥231.75B (+19.2%). Non-operating financial expenses were minimal at ¥0.09B, and recurring business earnings continued to drive profit growth, resulting in higher revenue and profit.
Key Financial Indicators
【Profitability】The operating margin improved by +0.9pt to 48.2% from 47.3% in the previous year, while the net profit margin expanded by +1.3pt to 34.9% from 33.6%. The gross margin also improved to 70.3% from 69.6%, confirming enhanced profitability in both pricing and product mix.【Cash Flow Quality】Operating cash flow (OCF) was ¥249.10B, providing approximately 1.07x coverage of net income of ¥231.75B, indicating a favorable cash conversion rate.【Investment Efficiency】ROE was 11.4%, comprising a combination of a 34.9% net profit margin, approximately 0.27x total asset turnover, and approximately 1.21x financial leverage. The improvement in the profit margin was the primary driver of the increase in ROE.【Financial Soundness】The equity ratio increased by +0.7pt to 82.8% from 82.1% in the previous year. Cash and cash equivalents were ¥390.44B, while non-current liabilities remained limited to ¥30.06B, demonstrating that the capital structure continues to be conservative.
Cash Flow Analysis
OCF increased significantly by 33.9% YoY to ¥249.10B, representing the subtotal of OCF of ¥338.60B after deducting income taxes and other taxes paid of ¥89.50B. Investing cash flow was an outflow of ¥36.05B, centered on capital expenditures of ¥21.23B and the acquisition of intangible assets and other items, narrowing from the previous year’s outflow of ¥133.47B. As a result, free cash flow, calculated as the sum of OCF and investing cash flow, was ¥213.05B, a substantial increase from ¥52.62B in the previous year. Financing cash flow was an outflow of ¥250.87B, of which dividend payments accounted for ¥241.92B, resulting in a larger outflow than the previous year’s ¥97.84B. Cash and cash equivalents decreased to ¥390.44B at period-end from ¥426.60B in the previous year. This was because financing activities, primarily dividend payments, exceeded the ample funds generated by operating activities; the business’s underlying cash-generation capacity itself strengthened from the previous year.
Quality of Earnings
Net income was ¥231.75B after deducting income taxes and other taxes of ¥97.47B (effective tax rate: 29.6%; previous year: 28.5%) from profit before tax of ¥329.22B. The higher tax burden slightly limited net income growth (+19.2%) relative to profit-before-tax growth (+21.1%). Financial expenses were minimal at ¥0.09B, and distortions from non-operating gains and losses were limited, with the majority of earnings generated by recurring business activities. Comprehensive income was ¥247.47B, exceeding net income by ¥15.72B (+6.8%). This difference was mainly attributable to other comprehensive income related to cash flow hedges (+¥13.94B) and foreign currency translation adjustments (+¥1.89B), which are valuation-related factors separate from the profitability of the underlying business. With OCF remaining at approximately 1.07x net income, the level of accruals was not significant, and earnings quality can generally be assessed as stable.
Earnings Forecasts and Guidance
No revisions were made to the earnings forecast or dividend forecast during the quarter. As specific full-year forecast figures for revenue and profit have not been disclosed, progress rates cannot be calculated; however, first-half results indicate that revenue and profit are progressing at a pace exceeding the same period of the previous year.
Shareholder Returns
The interim dividend for the current period was ¥66 per share, consisting solely of the regular dividend, a decrease of -47.2% from ¥125 in the same period of the previous year, comprising a regular dividend of ¥50 plus a 100th anniversary commemorative dividend of ¥75. This decrease was due to the conclusion of the commemorative dividend, while the regular dividend itself increased from ¥50 to ¥66. Based on the interim dividend of ¥66 and the average number of shares outstanding during the period (approximately 1.65B shares), total dividends are calculated at approximately ¥108.6B, resulting in a payout ratio of approximately 46.9% against first-half net income of ¥231.75B. Actual dividend payments reported in financing cash flow were ¥241.92B, including the year-end dividend for the previous fiscal period. Given OCF of ¥249.10B and free cash flow of ¥213.05B, dividends are adequately supported by cash generation. Together with the conservative financial structure reflected in the equity ratio of 82.8%, the foundation supporting dividend sustainability can be considered robust.
Risk Factors
-
Relative decline in the R&D investment ratio: Although R&D expenses increased to ¥89.64B (+3.5% YoY), R&D expenses as a percentage of revenue declined to 13.5% from 15.0% in the previous year. While R&D expense growth was moderate relative to revenue growth (+14.7%) and contributed to improved profit margins, the trend in the scale of medium- to long-term R&D investment should be monitored.
-
Increase in inventories and inventory management: Inventories increased 14.7% YoY to ¥317.58B, expanding at approximately the same rate as revenue. Inventory turnover days have lengthened slightly from the previous year, increasing the relative importance of quality and shelf-life management unique to biopharmaceuticals.
-
Increase in the effective tax rate: The effective tax rate increased to 29.6% from 28.5% in the previous year, somewhat suppressing net income growth (+19.2%) relative to profit-before-tax growth (+21.1%). The impact of future tax reforms and changes in the geographic allocation of profits should continue to be monitored.
Industry Benchmark (Reference; Compiled by the Company)
Industry Benchmark (pharma)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 48.2% | – | – |
| Net Profit Margin | 34.9% | – | – |
Both the operating margin and net profit margin are at extremely high levels, suggesting that the company ranks among the leaders in the industry in terms of profitability.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 14.7% | – | – |
The revenue growth rate indicates double-digit growth, suggesting a high growth pace within the industry.
Source: Compiled by the Company
Key Takeaways from the Earnings Results
-
Operating income (+16.9%) and net income (+19.2%) grew at a faster pace than revenue growth (+14.7%), improving the operating margin to 48.2% (+0.9pt) and the net profit margin to 34.9% (+1.3pt), indicating a sustained improvement in profitability.
-
While maintaining a conservative financial base with an equity ratio of 82.8%, OCF increased 33.9% YoY and free cash flow expanded substantially, demonstrating simultaneous progress in profitability improvement and cash-generation capacity.
-
The interim dividend decreased from ¥125 in the same period of the previous year to ¥66, but this was due to the conclusion of the 100th anniversary commemorative dividend. The increase in the regular dividend from ¥50 to ¥66 is noteworthy as a structural change.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
Chugai Pharmaceutical delivered a strong FY2026 Q2 result, combining double-digit sales growth, further margin expansion, high cash conversion and a very resilient balance sheet. Revenue increased 14.7% year on year to ¥663.3bn. Operating income rose faster than revenue, up 16.9% to ¥319.6bn. Net income increased 19.2% to ¥231.7bn, outperforming both revenue and operating-profit growth. Gross profit grew 15.8% to ¥466.3bn, lifting the gross margin by approximately 70bp year on year to 70.3%. Operating margin expanded by approximately 90bp to 48.2%, an exceptionally high level for the pharmaceutical sector. Net margin improved by approximately 130bp to 34.9%. R&D expenditure increased 3.4% to ¥89.6bn, but growth was materially below revenue growth, reducing R&D intensity to 13.5% from approximately 15.0% a year earlier. SG&A rose 12.2% to ¥57.9bn, also below sales growth, demonstrating favorable operating leverage. Annualized ROE was 22.9%, supported principally by the 34.9% net margin rather than balance-sheet leverage. Operating cash flow of ¥249.1bn exceeded net income, producing an OCF/net-income ratio of 1.07x and supporting the quality of reported earnings. Free cash flow reached ¥213.1bn after ¥21.2bn of capital expenditure, up substantially from the prior-year level. The balance sheet remains highly liquid, with an 82.8% equity ratio, a calculated current ratio of approximately 4.35x, and D/E of only 0.21x. Cash and equivalents declined ¥36.2bn year on year to ¥390.4bn, primarily because dividends paid of ¥241.9bn exceeded the period's free cash flow. Working-capital intensity is nevertheless a material operational issue: DSO was 105 days, DIO was 294 days and the cash conversion cycle was 250 days. Inventories rose 14.7% year on year to ¥317.6bn, broadly in line with sales, while trade receivables declined 13.8% to ¥381.8bn, indicating that the high DSO should be monitored in the context of the company's sales and collection mix. The Q2 DPS of ¥66 implies a stated dividend payout ratio of 47.8%, within a sustainable range based on earnings and current-period free cash flow. The announced FY2026 dividend forecast is ¥132 per share and has not been revised. Overall, the results reinforce the company's superior profitability and cash-generative profile, while inventory management, cash-cycle discipline, pipeline execution, and the sustainability of margin expansion remain central forward-looking issues.
Profitability Analysis
The annualized DuPont ROE of 22.9% decomposes into a 34.9% net profit margin, 0.542x asset turnover, and 1.21x financial leverage. Profitability, rather than leverage, is the dominant driver of returns: financial leverage is modest and consistent with the 82.8% equity ratio. The net margin rose by approximately 130bp year on year from 33.6%, representing the most important favorable DuPont movement evident in the period. Gross margin increased approximately 70bp to 70.3%, while operating margin expanded approximately 90bp to 48.2%, showing that revenue growth translated efficiently through the cost base. Revenue grew 14.7%, ahead of SG&A growth of 12.2% and R&D growth of 3.4%, creating favorable operating leverage. R&D intensity was 13.5% of revenue, below the 15-20% innovator-pharma reference range and down from approximately 15.0% in the comparable period; this improves near-term margins but makes continued investment in clinical development and drug discovery an important issue for long-term franchise renewal. The tax burden was 0.704, indicating that 70.4% of pre-tax profit converted to net income, while the 29.6% effective tax rate rose by roughly 110bp year on year. The interest burden of 1.030 reflects net non-operating income rather than debt dependence, with finance costs only ¥0.9bn. The 0.542x annualized asset turnover is appropriate for a high-margin, R&D-intensive pharmaceutical model, although the 294-day inventory holding period constrains balance-sheet efficiency. The 48.2% EBIT margin and 34.9% net margin substantially exceed standard excellent-profitability benchmarks and provide significant capacity to absorb pricing, currency, or product-mix volatility.
Growth Assessment
Top-line growth of 14.7% and operating-profit growth of 16.9% indicate a high-quality expansion phase, with earnings scaling more quickly than revenue. Gross profit growth of 15.8% exceeded sales growth, confirming a modest improvement in product economics and/or sales mix. Net income growth of 19.2% exceeded operating-income growth, helped by the favorable relationship between pre-tax income of ¥329.2bn and operating income of ¥319.6bn. The operating model showed continued cost discipline, as both SG&A and R&D grew more slowly than revenue. This cost leverage is supportive of near-term earnings growth, but the decline in R&D intensity to 13.5% warrants attention for an innovator pharmaceutical company because sustained pipeline investment is necessary to offset patent-expiry and clinical-development risks. Inventories increased 14.7%, exactly matching sales growth, which may reflect preparation for continued demand but leaves substantial capital tied up in stock. The absence of a revision to the ¥132 full-year DPS forecast signals continuity in capital-return expectations. Management presents forecasts on a Core basis under IFRS, adjusting items it considers non-recurring; investors should therefore compare future Core performance with IFRS results carefully when assessing recurring profitability and shareholder distributions. Revenue sustainability will principally depend on maintaining product demand, successful pipeline progression, regulatory execution, and resilience against pharmaceutical pricing pressure.
Financial Health
Financial health is exceptionally strong. Total equity was ¥2,027.7bn against total liabilities of ¥422.3bn, producing an 82.8% equity ratio and D/E of 0.21x. Current assets of ¥1,704.2bn were approximately 4.35x estimated current liabilities of ¥392.2bn, well above the 1.5x healthy-current-ratio benchmark. Estimated working capital was ¥1,312.0bn, providing a substantial liquidity buffer. Cash and equivalents of ¥390.4bn alone covered estimated current liabilities by approximately 1.0x. Non-current liabilities were only ¥30.1bn, so there is no evident maturity mismatch between short-term obligations and liquid current assets. Trade payables increased 26.3% year on year to ¥160.7bn, exceeding the threshold for a notable balance-sheet movement. The higher payable balance partially supports operating working capital, although it should be monitored alongside the long inventory cycle to assess whether supplier-payment timing is becoming a larger source of cash funding. Income taxes payable rose to ¥101.1bn from ¥91.0bn, consistent with the higher earnings base. PPE increased 5.5% year on year to ¥481.6bn, while intangible assets represented only 2.4% of total assets, limiting acquisition-related intangible-asset concentration. Right-of-use assets were modest at ¥21.9bn, and defined-benefit liabilities were limited at ¥4.9bn. Overall solvency is conservative, with ample capacity to fund R&D, manufacturing investment, dividends, and potential business-development activities from internally generated resources.
Notable B/S Changes
Accounts payable: +¥33.5bn (+26.3%) to ¥160.7bn - increased supplier obligations provide some working-capital funding, but should be monitored alongside the elevated 294-day inventory cycle and 250-day cash conversion cycle.
Cash Flow Quality
Cash-flow quality was high in FY2026 Q2. Operating cash flow was ¥249.1bn, exceeding net income of ¥231.7bn and producing an OCF/net-income ratio of 1.07x, above the 1.0x high-quality benchmark. The accruals ratio was -0.7%, also consistent with strong cash-backed earnings and limited accrual-related concern. Operating cash flow increased 33.9% year on year, faster than the 19.2% increase in net income. Cash generation remained robust after income tax payments of ¥89.5bn. Free cash flow was ¥213.1bn after capital expenditure of ¥21.2bn, equivalent to approximately 92% of net income and representing strong conversion of accounting profit into discretionary cash. Capital expenditure was significantly lower than the ¥48.9bn recorded in the prior-year period, which contributed to the improvement in free cash flow and should be assessed over a longer horizon alongside manufacturing-capacity needs. Intangible-asset purchases were ¥9.9bn, reflecting ongoing but manageable investment in intellectual-property-related assets. Other working-capital changes were a ¥13.3bn cash outflow, modest relative to operating cash flow. However, the 250-day cash conversion cycle is a material efficiency concern. DSO of 105 days is well above the 60-day alert threshold, indicating a prolonged receivable collection period. DIO of 294 days is substantially above both the 90-day and 60-day thresholds, indicating considerable inventory funding needs and exposure to demand forecasting, product obsolescence, and supply-chain execution risk. The fall in receivables year on year is encouraging, but the absolute receivable balance remains large at ¥381.8bn. Financing cash flow was a ¥250.9bn outflow, primarily due to ¥241.9bn of dividends paid, and resulted in a ¥36.2bn decline in cash despite strong operating cash generation.
Dividend Sustainability
The Q2 dividend was ¥66 per share, and the stated payout ratio was 47.8%, below the 60% sustainability benchmark. Free cash flow of ¥213.1bn covered the stated period dividend requirement by 1.92x, indicating sound underlying dividend affordability. The full-year dividend forecast is ¥132 per share and has not been revised. Dividend payments made during the period totaled ¥241.9bn and exceeded current-period free cash flow, resulting in a financing-driven cash outflow and a reduction in cash balances. This cash-payment profile does not undermine sustainability given the company's ¥390.4bn cash balance, low leverage, and strong operating cash generation, but it means dividend timing can temporarily exceed intra-period FCF. The company retains substantial financial flexibility because D/E is only 0.21x and the equity ratio is 82.8%. Sustained dividend growth will depend on preserving the high-margin earnings base, maintaining cash conversion, and avoiding a material deterioration in the inventory and receivables cycle. The current dividend policy outlook appears supported by profitability and liquidity rather than by incremental borrowing.
Risk Assessment
Business risks include Pharmaceutical pipeline and clinical risk: R&D intensity was 13.5%, below the 15-20% innovator-pharma reference range; successful progression of discovery and clinical assets is necessary to sustain long-term growth as existing product franchises mature., Patent-expiry, biosimilar/generic competition and healthcare-pricing risk: the very high 48.2% operating margin provides a buffer, but it also creates sensitivity to changes in product mix, reimbursement, price controls, and competitive entry., Inventory-management risk: DIO of 294 days is substantially above sector alert thresholds. High inventory can lead to write-down, expiry, demand-forecasting, manufacturing-planning, and supply-chain risks if sales momentum changes., Receivables-management risk: DSO of 105 days is above the 60-day alert threshold. Although receivables fell year on year, extended collection periods increase working-capital requirements and exposure to customer or payer settlement timing..
Financial risks include Cash conversion cycle risk: the 250-day cash conversion cycle exceeds the 120-day alert threshold, leaving a significant amount of capital tied up in receivables and inventories despite strong reported cash conversion in the period., Dividend cash-timing risk: ¥241.9bn of dividends paid exceeded ¥213.1bn of free cash flow during the period, reducing cash and equivalents by ¥36.2bn. The risk is mitigated by the large cash balance and conservative capital structure., Payables movement risk: trade payables rose 26.3% to ¥160.7bn. This supports near-term cash flow, but a sustained increase faster than underlying procurement activity could signal greater reliance on supplier financing..
Key concerns include The most material operational warning is working-capital efficiency rather than leverage or liquidity: DSO, DIO and the cash conversion cycle all exceed stated quality-alert thresholds., Margin expansion has been helped by R&D and SG&A growing below revenue. Sustaining this profile without impairing future pipeline productivity is an important strategic balancing issue., The investment case remains sensitive to the durability of high-margin pharmaceutical product demand, regulatory approvals, reimbursement conditions, and competitive dynamics..
Investment Implications
Key takeaways include FY2026 Q2 delivered strong operating momentum: revenue grew 14.7%, operating income 16.9%, and net income 19.2%., Profitability is exceptional, with a 70.3% gross margin, 48.2% operating margin, 34.9% net margin and 22.9% annualized ROE., Earnings were cash-backed: OCF/net income was 1.07x, accruals were -0.7%, and free cash flow was ¥213.1bn., Capital structure is highly defensive, with an 82.8% equity ratio, 0.21x D/E and an estimated 4.35x current ratio., The principal area requiring scrutiny is operating working capital, especially 294-day inventory days and a 250-day cash conversion cycle..
Metrics to watch include Revenue growth and operating-margin progression, R&D expenditure growth and R&D intensity, DSO, DIO, cash conversion cycle and inventory write-downs, Operating cash flow and free cash flow relative to net income and dividend payments, Receivables, inventories and trade payables relative to sales and cost of sales, Dividend payout ratio and cash balance following shareholder distributions, Pipeline milestones, regulatory outcomes, competitive entry and reimbursement developments.
Regarding relative positioning, Chugai is positioned as a high-margin, cash-generative innovator pharmaceutical company with unusually low financial leverage and substantial liquidity. Its annualized 22.9% ROE is driven by operating profitability rather than leverage, which is a favorable quality characteristic. Relative to standard pharmaceutical benchmarks, the 70.3% gross margin and 48.2% operating margin are outstanding, while the 13.5% R&D intensity and elevated working-capital cycle are the main areas for continued scrutiny.